Nav: Home

Abbreviated MRI outperforms 3D mammograms at finding cancer in dense breasts

February 25, 2020

According to a study published today in the Journal of the American Medical Association, abbreviated breast magnetic resonance imaging (MRI) detected significantly more cancers than digital breast tomosynthesis (3-D mammography) in average-risk women with dense breast tissue. The study compared the 10-minute MRI exam to 3-D mammography, in women with dense breasts, because the ability of mammography to detect breast cancer is limited in these women. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) designed and conducted the study (EA1141) with funding from the National Cancer Institute, part of the National Institutes of Health, and Bracco Diagnostics Inc. (Monroe Township, NJ).

According to Christopher E. Comstock, MD, the publication's lead author, "When screening women at average risk with dense breasts, we found that abbreviated breast MRI detected significantly more (almost two and a half times as many) breast cancers as 3-D mammography. We also found that the abbreviated breast MRI was well tolerated by women, with very few side effects."

Dr. Comstock is Attending Radiologist and Director of Breast Imaging Clinical Trials at Memorial Sloan Kettering Cancer Center and Imaging Chair for ECOG-ACRIN's Breast Cancer Committee. Study leadership included breast cancer researchers from Memorial Sloan Kettering Cancer Center, University Hospital of RWTH Aachen, University of Chicago, University of Pennsylvania and the Department of Biostatistics and Center for Statistical Sciences at Brown University School of Public Health.

Despite current screening methods, over 40,000 women die each year from breast cancer. The ability of mammography to detect breast cancer is especially limited in women with dense breast tissue. Having dense breasts is not an abnormal condition; in fact, about half of all women over the age of 40 have dense breasts.

Breast MRI is a screening test that uses radio waves to capture images following intravenous injection of contrast dye. Because it is not limited by breast density, MRI offers the highest cancer detection rate of all breast imaging modalities. However, breast MRI is more expensive than a mammogram, takes longer to perform (45 minutes compared to about 15 minutes for a mammogram) and requires an injection.

Although most evidence exists for using MRI to screen the small proportion of women at very high risk of breast cancer, there is accumulating evidence, pioneered by Christiane K. Kuhl, MD, PhD (Chairman of Radiology at University Hospital Aachen and the publication's senior author), that the higher sensitivity of MRI is also seen in women at average risk.

As Dr. Comstock explained, "Although MRI is undoubtedly the most sensitive test for detecting breast cancer, it is not being used to screen the large number of average-risk women with dense breasts due to its high cost and time to perform. Abbreviated breast MRI is a 10-minute test that reduces the complexity and cost of MRI by shortening the time it takes to perform and interpret the exam. The EA1141 results will hopefully give far more women access to this powerful tool in the fight against breast cancer."

The EA1141 study compared the diagnostic performance of abbreviated breast MRI to 3-D mammography in screening average-risk women with dense breasts for breast cancer.

Women were eligible to participate in the study if they were between the ages of 40 and 75, had dense breasts on their prior mammogram, and did not currently have breast cancer or any clinical symptoms. This analysis pertains to 1,444 trial participants, all of whom were screened with both 3-D mammography and abbreviated MRI within 24 hours. The images were interpreted independently by two different board-certified breast radiologists who remained blinded to the results of the other modality.

Participants were screened twice in the study, first as a baseline and again after one year, and are being followed for three additional years. Enrollment took place over 11 months (December 2016 - November 2017) at 47 centers in the US and one in Germany. The US centers are a mixture of academic, community hospital, and private institutions throughout the country.

In the first year of the study, 23 women were diagnosed with breast cancer. The abbreviated MRI detected 22 out of the 23 women with breast cancer, while the 3-D mammogram detected only nine out of the 23 women. Abbreviated MRI detected all of the cancers found on 3-D mammography except for one early stage cancer. At the same time, abbreviated MRI found an additional 10 invasive breast cancers, including three high-grade cancers, which were not detected on 3-D mammography.

There were no patients with interval cancers, which are cancers detected within 12 months after a screening exam interpreted as normal. However, the abbreviated MRI led to slightly more false-positive results, including recommendations for biopsies of findings that turned out not to be cancer.

The EA1141 study looked solely at women with dense breasts. It provides promising results for abbreviated MRI, and may ultimately help better screen women with dense breasts for cancer. The study did not attempt to provide cancer mortality information.

According to Dr. Comstock, "While these early results are promising, further studies are needed to evaluate the cost-effectiveness of widespread screening with abbreviated breast MRI and its impact on reducing breast cancer mortality. Currently, only a few centers offer abbreviated breast MRI and it is not covered by insurance. Our hope is that study EA1141 will provide the impetus for more centers to provide this new test and that insurers will see its benefit to improve early detection of breast cancer."
The publication title is "Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women with Dense Breasts Undergoing Screening."

The federal record for study EA1141 on is NCT02933489.

About the ECOG-ACRIN Cancer Research Group

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) is a membership-based scientific organization that designs and conducts cancer research involving adults who have or are at risk of developing cancer. ECOG-ACRIN comprises nearly 1100 member institutions in the United States and around the world. Approximately 12,000 physicians, translational scientists and associated research professionals from the member institutions are involved in Group research, which is organized into three scientific programs: Cancer Control and Outcomes, Therapeutic Studies, and Biomarker Sciences. ECOG-ACRIN is supported primarily through National Cancer Institute research grant funding, but also receives funding from private sector organizations through philanthropy and collaborations. Its headquarters are in Philadelphia, Pa. For more information, visit, follow us on Twitter @eaonc, Facebook, and LinkedIn, or call 215.789.3631.

ECOG-ACRIN Cancer Research Group

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at